Xencor (XNCR) News Today

Xencor (NASDAQ:XNCR) Stock Price Down 4%

Xencor (NASDAQ:XNCR) Sees Large Volume Increase

Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Xencor in a research note on Monday.

Xencor (NASDAQ:XNCR) Shares Gap Up to $16.18

Candriam S.C.A. trimmed its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 52.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 310,019 shares of the biopharmaceutical company's stock after

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has

Panagora Asset Management Inc. lifted its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 9.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 232,375 shares of the biopharmaceutical company's stock after purchasing

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Leerink Partnrs cut their Q3 2024 earnings per share estimates for shares of Xencor in a report issued on Wednesday, August 21st. Leerink Partnrs analyst J. Chang now forecasts that the biopharmaceutical company will post earnings of ($1.18) per share fo

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received a consensus recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and on

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for shares of Xencor in a report issued on Tuesday, August 6th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings per

Xencor (NASDAQ:XNCR) Reaches New 52-Week Low at $16.00

Xencor (NASDAQ:XNCR - Get Free Report) released its earnings results on Monday. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.25). The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The company's revenue for the quarter was down 62.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) EPS.

Royal Bank of Canada restated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research note on Tuesday.

Vanguard Group Inc. boosted its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 3.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,011,042 shares of the biopharmaceutical company's stock after purchasing an add

JPMorgan Chase & Co. lowered their price target on shares of Xencor from $30.00 to $27.00 and set an "overweight" rating for the company in a report on Wednesday.

Jacobs Levy Equity Management Inc. bought a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 208,227 shares of the biopharmaceutical company's stock, valued at approximately $4

Price T Rowe Associates Inc. MD raised its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 3,819,656 shares of the biopharmaceutical company's stock after acquiring an additional 335,881

Xencor (NASDAQ:XNCR) Shares Up 4.8%

Russell Investments Group Ltd. lifted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 43.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 224,140 shares of the biopharmaceutical company's stock after buying an additiona

BNP Paribas Financial Markets decreased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 44.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,795 shares of the biopharmaceutical company's stock

Entropy Technologies LP acquired a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 25,886 shares of the biopharmaceutical company's stock, valued at approximately $57

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 4,830,000 shares, a decrease of 12.9% from the June 15th total of 5,544,900 shares. Based on an average daily volume of 622,400 shares, the short-interest ratio is presently 7.8 days.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John R. Desjarlais sold 36,329 shares of the business's stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the sale, the vice president now directly owns 192,319 shares in the company, valued at $3,523,284.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vanguard Group Inc. boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,767,249 shares of the biopharmaceutical company's stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has been given an average rating of "Buy" by the eight ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a str

Xencor (NASDAQ:XNCR) Share Price Passes Below 200 Day Moving Average of $21.49

BMO Capital Markets lowered their price target on shares of Xencor from $34.00 to $32.00 and set an "outperform" rating on the stock in a research note on Friday.

Wedbush restated an "outperform" rating and issued a $34.00 price objective (down from $36.00) on shares of Xencor in a research report on Thursday.

TD Asset Management Inc lowered its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 31.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,250 shares of the biopharmaceutical company's

Norges Bank bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 325,439 shares of the biopharmaceutical company's stock, valued